For patients with insulin resistance or pre-diabetes, this metabolic correction has benefits that extend well beyond weight loss
A Phase 2 study published in The New England Journal of Medicine (Jastreboff et al., 2023) reported substantial weight reduction in participants with obesity
For example, in Canada, attention is already shifting towards newer entrants like tirzepatide (Mounjaro/Zepbound), which has demonstrated superior efficacy in weight loss in the head-to-head SURMOUNT-5 trial iii and is gaining momentum
While glutathione is widely known for protecting cells from damage, the team found that cancer cells can hijack it and use it as a nutrient, particularly in environments where other resources are scarce
This includes prioritizing drugs with proven outcome benefits in those at high risk, even as metformin remains appropriate for many others
doi: 10.1016/j.biomaterials.2025.123387